LivaNova 향후 성장

Future 기준 점검 3/6

LivaNova (는) 각각 연간 67.1% 및 5.7% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 67.3% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 8.2% 로 예상됩니다.

핵심 정보

67.1%

이익 성장률

67.29%

EPS 성장률

Medical Equipment 이익 성장	12.7%
매출 성장률	5.7%
향후 자기자본이익률	8.20%
애널리스트 커버리지	Good
마지막 업데이트	01 Oct 2025

최근 향후 성장 업데이트

LivaNova PLC Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Feb 28

LivaNova PLC Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year

Nov 03

Recent updates

Optimistic Investors Push LivaNova PLC (NASDAQ:LIVN) Shares Up 28% But Growth Is Lacking

Aug 17

Investment In Obstructive Sleep Apnea And DTD Therapies Will Strengthen Future Market Position

Mar 11 Strategic focus on obstructive sleep apnea and cardiopulmonary advancements is key for revenue growth and market expansion.

LivaNova PLC Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Feb 28

We Like These Underlying Return On Capital Trends At LivaNova (NASDAQ:LIVN)

Feb 25

LivaNova PLC's (NASDAQ:LIVN) Price Is Right But Growth Is Lacking

Dec 28

We Think LivaNova's (NASDAQ:LIVN) Profit Is Only A Baseline For What They Can Achieve

Nov 12

LivaNova PLC Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year

Nov 03

LivaNova (NASDAQ:LIVN) Is Experiencing Growth In Returns On Capital

Oct 31

LivaNova: Economics Should Start Making Sustained Improvements

Oct 18

Are Investors Undervaluing LivaNova PLC (NASDAQ:LIVN) By 31%?

Oct 02

LivaNova PLC's (NASDAQ:LIVN) Prospects Need A Boost To Lift Shares

Aug 21

LivaNova (NASDAQ:LIVN) Might Have The Makings Of A Multi-Bagger

Jul 30

At US$52.79, Is It Time To Put LivaNova PLC (NASDAQ:LIVN) On Your Watch List?

Jul 04

Is LivaNova PLC (NASDAQ:LIVN) Trading At A 31% Discount?

Jun 13

LivaNova: Focus Is Paying Off

May 12

These Return Metrics Don't Make LivaNova (NASDAQ:LIVN) Look Too Strong

Apr 08

Is It Time To Consider Buying LivaNova PLC (NASDAQ:LIVN)?

Feb 05

A Look At The Intrinsic Value Of LivaNova PLC (NASDAQ:LIVN)

Jan 15

LivaNova PLC's (NASDAQ:LIVN) Business And Shares Still Trailing The Industry

Dec 25

LivaNova (NASDAQ:LIVN) Could Be At Risk Of Shrinking As A Company

Nov 29

We Think LivaNova's (NASDAQ:LIVN) Profit Is Only A Baseline For What They Can Achieve

Nov 08

At US$47.94, Is LivaNova PLC (NASDAQ:LIVN) Worth Looking At Closely?

Oct 16

Are Investors Undervaluing LivaNova PLC (NASDAQ:LIVN) By 44%?

Sep 25

Capital Allocation Trends At LivaNova (NASDAQ:LIVN) Aren't Ideal

Jul 26

Should You Investigate LivaNova PLC (NASDAQ:LIVN) At US$51.43?

Jul 03

An Intrinsic Calculation For LivaNova PLC (NASDAQ:LIVN) Suggests It's 37% Undervalued

Jun 09

이익 및 매출 성장 예측

NasdaqGS:LIVN - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)
날짜	매출	이익	자유현금흐름	영업현금흐름	평균 애널리스트 수
12/31/2027	1,544	166	N/A	N/A	7
12/31/2026	1,455	139	N/A	N/A	9
12/31/2025	1,368	-243	N/A	N/A	10
6/30/2025	1,309	-211	162	217	N/A
3/31/2025	1,275	-222	146	197	N/A
12/31/2024	1,253	63	136	183	N/A
9/30/2024	1,242	24	109	158	N/A
6/30/2024	1,210	-17	85	125	N/A
3/31/2024	1,185	-32	30	64	N/A
12/31/2023	1,154	18	40	75	N/A
9/30/2023	1,118	3	8	40	N/A
6/30/2023	1,085	-97	29	57	N/A
3/31/2023	1,045	-82	36	65	N/A
12/31/2022	1,022	-86	43	70	N/A
9/30/2022	1,017	-93	60	85	N/A
6/30/2022	1,018	-29	51	73	N/A
3/31/2022	1,028	-102	86	109	N/A
12/31/2021	1,035	-136	77	103	N/A
9/30/2021	1,035	-414	82	106	N/A
6/30/2021	1,022	-385	59	91	N/A
3/31/2021	939	-417	11	46	N/A
12/31/2020	934	-347	-114	-79	N/A
9/30/2020	952	-208	-150	-114	N/A
6/30/2020	981	-161	-234	-199	N/A
3/31/2020	1,076	-102	-230	-199	N/A
12/31/2019	1,084	-158	-116	-91	N/A
9/30/2019	1,094	-222	-106	-73	N/A
6/30/2019	1,097	-260	19	55	N/A
3/31/2019	1,107	-211	N/A	102	N/A
12/31/2018	1,107	-178	N/A	120	N/A
9/30/2018	1,088	0	N/A	117	N/A
6/30/2018	1,068	33	N/A	108	N/A
3/31/2018	1,036	59	N/A	79	N/A
12/31/2017	1,012	54	N/A	91	N/A
9/30/2017	795	121	N/A	114	N/A
6/30/2017	840	92	N/A	109	N/A
3/31/2017	905	55	N/A	114	N/A
12/31/2016	965	2	N/A	90	N/A
12/31/2015	545	-22	N/A	-14	N/A
10/18/2015	295	14	N/A	87	N/A
7/24/2015	301	57	N/A	80	N/A
4/24/2015	292	58	N/A	80	N/A
1/23/2015	292	66	N/A	80	N/A
10/24/2014	288	63	N/A	75	N/A

애널리스트 향후 성장 전망

수입 대 저축률: LIVN 은 향후 3년 동안 수익을 낼 것으로 예상되며, 이는 절약률(3.1%)보다 빠른 성장으로 간주됩니다.

수익 vs 시장: LIVN (는) 향후 3년 동안 평균 시장 성장보다 높은 수익을 올릴 것으로 예상됩니다.

고성장 수익: LIVN 향후 3년 내에 수익을 낼 것으로 예상됩니다.

수익 대 시장: LIVN 의 수익(연간 5.7%)이 US 시장(연간 9.8%)보다 느리게 성장할 것으로 예상됩니다.

고성장 매출: LIVN 의 수익(연간 5.7%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.

주당순이익 성장 예측

향후 자기자본이익률

미래 ROE: LIVN의 자본 수익률은 3년 후 8.2%로 낮을 것으로 예상됩니다.

성장 기업 찾아보기

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2025/10/03 15:48
종가	2025/10/03 00:00
수익	2025/06/30
연간 수익	2024/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 Github 페이지에서 확인할 수 있으며, 보고서 활용 방법에 대한 가이드와 Youtube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

LivaNova PLC는 32명의 분석가가 다루고 있습니다. 이 중 10명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
Michael Polark	Baird
David Rescott	Baird
Matthew Miksic	Barclays

LivaNova 향후 성장

Future 기준 점검 3/6

핵심 정보

최근 향후 성장 업데이트

LivaNova plc Updates Earnings Guidance for the Full Year 2025

Consensus EPS estimates fall by 177%

LivaNova PLC Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Price target decreased by 7.9% to US$63.40

LivaNova PLC Provides Earnings Guidance for the Full-Year 2025

LivaNova PLC Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year

Recent updates

LivaNova PLC Appoints Donald Zurbay to Board of Director and Audit and Compliance Committee, Effective September 4, 2025

LivaNova PLC Launches Essenz Perfusion System in China

Optimistic Investors Push LivaNova PLC (NASDAQ:LIVN) Shares Up 28% But Growth Is Lacking

Second quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

LivaNova plc Updates Earnings Guidance for the Full Year 2025

LivaNova (NASDAQ:LIVN) Has A Pretty Healthy Balance Sheet

LivaNova PLC to Report Q2, 2025 Results on Aug 06, 2025

LivaNova: The Sell-Off Is Excessive Here

LivaNova (NASDAQ:LIVN) Is Experiencing Growth In Returns On Capital

LivaNova PLC(NasdaqGS:LIVN) dropped from Russell 2000 Growth Index

Livanova plc Announces Completion of the Core-Vns Study

LivaNova Initiates Process with U.S. Centers for Medicare and Medicaid Services for Reconsideration of National Coverage for VNS Therapy for Treatment-Resistant Depression

Consensus EPS estimates fall by 177%

First quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

LivaNova plc Announces 12-Month Data from Osprey Clinical Study for Moderate to Severe Obstructive Sleep Apnea, Demonstrating Strong Response and Durability of Therapy

LivaNova PLC, Annual General Meeting, Jun 11, 2025

With LivaNova PLC (NASDAQ:LIVN) It Looks Like You'll Get What You Pay For

LivaNova PLC to Report Q1, 2025 Results on May 07, 2025

Should You Think About Buying LivaNova PLC (NASDAQ:LIVN) Now?

Investment In Obstructive Sleep Apnea And DTD Therapies Will Strengthen Future Market Position

LivaNova PLC Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Price target decreased by 7.9% to US$63.40

Full year 2024 earnings: EPS exceeds analyst expectations

LivaNova PLC Provides Earnings Guidance for the Full-Year 2025

We Like These Underlying Return On Capital Trends At LivaNova (NASDAQ:LIVN)

LivaNova PLC to Report Q4, 2024 Results on Feb 25, 2025

LivaNova PLC Appoints Natalia Kozmina as Chief Human Resources Officer, Effective January 14, 2025

LivaNova PLC's (NASDAQ:LIVN) Price Is Right But Growth Is Lacking

We Think LivaNova's (NASDAQ:LIVN) Profit Is Only A Baseline For What They Can Achieve

LivaNova PLC Announces OSPREY Clinical Study Meets Primary Safety and Efficacy Endpoints

LivaNova PLC Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

High number of new directors

LivaNova (NASDAQ:LIVN) Is Experiencing Growth In Returns On Capital

LivaNova: Economics Should Start Making Sustained Improvements

LivaNova PLC Appoints Susan Podlogar as New Director

Are Investors Undervaluing LivaNova PLC (NASDAQ:LIVN) By 31%?

LivaNova PLC to Report Q3, 2024 Results on Oct 30, 2024

Trui Hebbelinck Leaves Position of LivaNova Plc's Chief Human Resources Officer

LivaNova PLC's (NASDAQ:LIVN) Prospects Need A Boost To Lift Shares

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

LivaNova PLC Provides Earnings Guidance for the Year 2024

LivaNova (NASDAQ:LIVN) Might Have The Makings Of A Multi-Bagger

At US$52.79, Is It Time To Put LivaNova PLC (NASDAQ:LIVN) On Your Watch List?

LivaNova PLC to Report Q2, 2024 Results on Jul 31, 2024

Daniel Jeffrey Moore Resigns as Director of LivaNova PLC

Is LivaNova PLC (NASDAQ:LIVN) Trading At A 31% Discount?

LivaNova PLC Provides Update on Recover Clinical Study Evaluating Vns Therapy for Treatment-Resistant Depression in Unipolar Patients

Independent Director notifies of intention to sell stock

LivaNova: Focus Is Paying Off

Now 21% undervalued

LivaNova PLC Provides Earnings Guidance for the Full-Year 2024

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

LivaNova PLC Announces Ahmet Tezel, Ph.D., as Chief Innovation Officer

LivaNova PLC, Annual General Meeting, Jun 11, 2024

These Return Metrics Don't Make LivaNova (NASDAQ:LIVN) Look Too Strong

Chief Financial Officer exercised options and sold US$353k worth of stock

LivaNova PLC to Report Q1, 2024 Results on May 01, 2024

Now 21% overvalued after recent price rise

LivaNova PLC Announces a Positive Predictive Outcome of Trial Success in its OSPREY Clinical Study for Moderate to Severe Obstructive Sleep Apnea

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates fall by 12%, revenue upgraded

Now 20% overvalued after recent price rise

Livanova plc Announces Impairment Charges for the Three Month Ended December 31, 2023

LivaNova PLC Announces CEO Changes, Effective on March 1, 2024

Is It Time To Consider Buying LivaNova PLC (NASDAQ:LIVN)?

A Look At The Intrinsic Value Of LivaNova PLC (NASDAQ:LIVN)

LivaNova PLC to Report Q4, 2023 Results on Feb 21, 2024

LivaNova PLC's (NASDAQ:LIVN) Business And Shares Still Trailing The Industry